Litcius/Paper detail

Telmisartan Restricts Chikungunya Virus Infection <i>In Vitro</i> and <i>In Vivo</i> through the AT1/PPAR-γ/MAPKs Pathways

Saikat De, Prabhudutta Mamidi, Soumyajit Ghosh, Supriya Suman Keshry, Chandan Mahish, Sweta Smita Pani, Eshna Laha, Amrita Ray, Ankita Datey, Sanchari Chatterjee, Sharad Singh, Tathagata Mukherjee, Somlata Khamaru, Subhasis Chattopadhyay, Bharat Bhusan Subudhi, Soma Chattopadhyay

2021Antimicrobial Agents and Chemotherapy28 citationsDOIOpen Access PDF

Abstract

Chikungunya virus (CHIKV) has reemerged as a global public health threat. The inflammatory pathways of the renin-angiotensin system (RAS) and peroxisome proliferator-activated receptor-gamma (PPAR-γ) are usually involved in viral infections.

Topics & Concepts

ChikungunyaVirusVero cellPeripheral blood mononuclear cellVirologyTelmisartanInflammationViral MyocarditisBiologyAgonistImmunologyViral life cycleMyocarditisImmune systemReceptorTLR3MedicineArthritisDengue virusProinflammatory cytokineInterferonAlphavirus infectionPharmacologyViral loadToll-like receptorMosquito-borne diseases and controlCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies
Telmisartan Restricts Chikungunya Virus Infection <i>In Vitro</i> and <i>In Vivo</i> through the AT1/PPAR-γ/MAPKs Pathways | Litcius